Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc reports the purchase of 1,500,000 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. The shares were bought on the London Stock Exchange/CBOE on 30 September 2025 at an average price of 331.3782 pence per share and will be held as treasury shares. After settlement the companys registered share capital is 8,952,353,648 ordinary shares, of which 44,400,783 are treasury shares, leaving 8,907,952,865 shares with voting rights. The announcement directs readers to a full breakdown of individual trades online.
Haleon plc announced the purchase of 1,996,340 ordinary shares under the second tranche of its buyback programme. The trades executed on the London Stock Exchange on 29 September 2025 at an average price of £330.3042 per share. The company intends to hold the purchased shares as treasury shares.
After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 42,900,783 are treasury shares, leaving 8,909,452,865 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company's investor website.
Haleon plc announced on 29 September 2025 that it purchased 1,996,340 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on the London Stock Exchange/CBOE (UK)/CXE on 26 September 2025 show prices reported between £325.1000 and £328.7000 with an average of £327.6614. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 40,904,443 are treasury shares, leaving 8,911,449,205 ordinary shares with voting rights. A full trade breakdown is available via the provided RNS link and the Company website.
Haleon plc filed a Form 6-K reporting a notification of transactions by persons discharging managerial responsibilities (PDMRs) under the UK Market Abuse Regulation. The notice, dated 26 September 2025, discloses a transaction price of £3.31963. The filing lists the company’s well-known brands including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren and directs readers to the corporate website. The report provides the required public disclosure of insider activity but does not include clear aggregated volume figures in the provided text, limiting assessment of the transaction’s size or investor impact.
Haleon plc reports a purchase of 2,318,700 ordinary shares under the second tranche of its share buyback programme. The trades occurred on the London Stock Exchange/CBOE (UK)/CXE on 25 September 2025 with reported trade price points shown as 329.7000, 325.9000 and a weighted average of 327.8536. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 38,908,103 are held as treasury shares, leaving 8,913,445,545 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the Company website.
Haleon plc announced on 25 September 2025 the purchase of 3,251,858 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. The purchases included 3,101,999 shares executed on 24 September 2025 on the London Stock Exchange CBOE (UK)/CXE at an average price of £330.4723 per share as shown in the trade breakdown. The Company intends to hold the acquired shares as treasury shares. After settlement the registered share capital is 8,952,353,648 ordinary shares, of which 36,589,403 are treasury shares, leaving 8,915,764,245 ordinary shares with voting rights for FCA disclosure guidance purposes. A full breakdown of individual trades is available at the provided RNS link and on the Company website.
Haleon plc (HLN) published a TR-1 notification reporting a significant shareholding held by Wellington Management group entities. The notification shows 418,575,113 direct voting rights, representing 4.69% of the company's voting rights. In addition, financial instruments reported in the notice amount to 26,175,050 voting rights (sub‑totals listed under 8.B1 and 8.B2), producing a total reported interest of 4.98% when instruments are included. The filing lists multiple Wellington controlled undertakings and indicates the chains of ownership through Wellington Management Group LLP and its affiliates that manage assets for funds and managed accounts. The disclosure is provided under the FCA/DTR rules as required for major holdings.
Haleon plc announced the purchase of 5,150,000 ordinary shares of £0.01 each on 23 September 2025 as part of the second tranche of its share buyback programme. The company intends to hold the purchased shares as treasury shares.
After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 33,337,545 are treasury shares, leaving 8,919,016,103 ordinary shares with voting rights. The announcement includes a link to a full breakdown of individual trades and clarifies it is not an offer for securities.
Haleon plc announced the purchase of 5,150,000 ordinary shares under the second tranche of its share buyback programme. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 28,187,545 are held as treasury shares, leaving 8,924,166,103 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided London Stock Exchange link and on the Company website.
Haleon plc reported small share purchases by two senior insiders through dividend reinvestment. On 18 September 2025, Chief Marketing Officer Tamara Rogers acquired 5 Ordinary Shares of £0.01 each at a price of £3.441 per share on the London Stock Exchange.
On the same date, Independent Non-Executive Director Alan Stewart acquired 214 Ordinary Shares at a price of £3.424442 per share, also via dividend reinvestment on the London Stock Exchange. These transactions were disclosed as required for persons discharging managerial responsibilities.